Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Corporate Presentation

Please select from the documents below
............................................................................................................................ 

Cardiff Oncology Corporate Presentation - March 2023